Table 1.
Baseline patient and psoriasis characteristics (N=713)
| Characteristic | N (%) |
|---|---|
| Age, mean, median (SD, IQR), y | 48.6, 49 (15.5, 38–60) |
| Female sex | 352 (49.37) |
| Practice setting of dermatologist | |
| Academic | 409 (57.36) |
| Private | 304 (42.64) |
| White/Caucasian race | 606 (84.99) |
| Body mass index (BMI) (kg/m2), median (IQR) | 28.8 (25.3, 33.0) |
| Total number of comorbidities, median (IQR)a | 2 (1–4) |
| Duration of psoriasis, median (IQR), y | 19 (8–29) |
| No. of days of topical medication use in last week, Median (IQR) | 2 (0–6) |
| Psoriatic arthritis diagnosed by a physician | 161 (22.58) |
| No. of previous biologic, oral systemic, or phototherapy treatments, median (IQR) | 1 (0–2) |
| Previous type(s) of psoriasis treatment usedb | |
| Biologic | 266 (37.31) |
| Oral systemic | 314 (44.04) |
| Phototherapy | 295 (41.37) |
| None | 184 (25.81) |
IQR, interquartile range; SD, standard deviation
Note: Percentages may not total 100% due to missing data, which did not exceed 1.5% for any particular characteristic.
a
Including cardiovascular, lung, infection, gastrointestinal, renal, endocrine, musculoskeletal, psychiatric, neurologic, malignant or autoimmune diseases
b
Percentages do not total 100% because some patients may have used more than one previous treatment